U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274020) titled 'Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients' on Oct. 01.
Brief Summary: Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency.
This ...